Improving women's health and sex life, Bionovo, BNVI

Monday, 23 January 2012 - staff

Bionovo, BNVI, Profile, Summary

Bionovo (BNVI) a clinical-stage drug discovery and development company, focuses on the development drug candidates in the areas of women's health and cancer. The company's drug development process utilizes botanical sources used in traditional Chinese medicine to produce biologically active compounds.

Bionovo's lead drug candidate, Menerba, which completed phase 2 clinical trail and progressing into phase 3.

Improving Women’s Health
40 million women in America are of menopausal age, an estimated 75% to 85% experience significant and unpleasant side effects due to declining and fluctuating hormone levels. These problems include vaginal dryness, depression and weight gain. Existing therapies represent a multi-billion dollar market. Bionovo is striving to provide a safe, reliable, and clinically proven therapy to fill this unmet need.

The company also develops Bezielle, an oral anti-cancer agent that completed two separate phase 1 clinical trails for the treatment of advanced breast cancer. Seala, a preclinical drug candidate for the treatment of post-menopausal vulvar and vaginal atrophy.

Conquering Cancer
Breast cancer is the second leading cause of cancer deaths in the United States, and more than 200,000 new cases are diagnosed each year. As a result, breast cancer takes more than 40,000 lives annually.

The company successfully raised funds and appointed new executives and board members. The stock is trading near 52WK LOWS could bounce back, keep an eye!

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we receive compensation from companies we feature. Always Read the full Disclosure/Disclaimer. Thanks. 

BPAX shareholders wonder if there is a Gel for stock dysfunction!

Tuesday, 17 January 2012 - staff

Female Sexual Dysfunction

BPAX shareholders wonder if there is a Gel for stock dysfunction! 

HOW BIG is the problem? And, How common is it? According to a recent study, conducted by the University of Chicago and published in the Journal of the American Medical Association, it apparently is a huge problem. 43% of women (aged 18 to 59) said they have experienced some degree of sexual dysfunction.

A SMALL pharmaceutical company wants to change all that and want to level the playing field for Women!

BioSante, BPAX, a specialist pharmaceutical company focused on Female health, wants to exploit the huge potential market opportunity. Men spent a whopping $5 Billion Dollars on Erectile Dysfunction drugs in 2011, according to the NY Times.

BioSante's answer LibiGel!  LibiGel is a transdermal testosterone gel in development for the treatment of Female Sexual Dysfunction – FSD -.

BioSante has completed two Phase III LibiGel safety and efficacy trials and is conducting a Phase III cardiovascular event and breast cancer safety study. The company is planning to submit a new drug application to the FDA by year-end 2012.

BioSante is an equal opportunity company, at least, when it comes to making money, so the company doesn't want to miss the rising demand from men.

For men BioSante is developing, Bio-T-Gel™ , a once-daily transdermal testosterone gel for the treatment of male hypogonadism, or low testosterone levels. Low testosterone affects more than 4 to 5 million men in the U.S, according to the company.

Is there are Gel for that?

stock holders wish there was one.

The Stock fell to the bottom gracelessly, still embarrassed and some what shameful, trading around its 52WK LOWS. We see a short to medium term bounce-back opportunity. Keep an eye.

Don't miss the NEXT premium Alert! Sign-up, Get Alerts, MakeMoney!®

we receive compensation from companies we feature. Always Read the full Disclosure/Disclaimer. Thanks.